Sustained low‐dose interleukin‐2 therapy alleviates pathogenic humoral immunity via elevating the Tfr/Tfh ratio in lupus

OBJECTIVES: Low‐dose interleukin‐2 (IL‐2) has shown promising clinical benefits in the treatment of systemic lupus erythematosus (SLE), but how this therapy alleviates pathogenic humoral immunity remains not well understood. The dilemma is that IL‐2 can suppress both follicular helper and regulatory...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Kaili, He, Jing, Wei, Yunbo, Zeng, Qunxiong, Gong, Dongcheng, Qin, Jiahuan, Ding, Huihua, Chen, Zhian, Zhou, Ping, Niu, Peng, Chen, Qian, Ding, Chenguang, Lu, Liangjing, Chen, Xiao‐Xiang, Li, Zhanguo, Shen, Nan, Yu, Di, Deng, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169300/
https://www.ncbi.nlm.nih.gov/pubmed/34094549
http://dx.doi.org/10.1002/cti2.1293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169300/
https://www.ncbi.nlm.nih.gov/pubmed/34094549
http://dx.doi.org/10.1002/cti2.1293

Ejemplares similares